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NASH is an Inﬂ  ammatory Disorder: Pathogenic, Prognostic and Therapeutic 
Implications
Geoffrey C. Farrell, Derrick van Rooyen, Lay Gan, and Shivrakumar Chitturi
Gastroenterology and Hepatology Unit, The Canberra Hospital, Australian National University Medical School, Garran, Australia
While non-alcoholic fatty liver disease (NAFLD) is highly 
prevalent (15% to 45%) in modern societies, only 10% to 
25% of cases develop hepatic fibrosis leading to cirrhosis, 
end-stage liver disease or hepatocellular carcinoma. Apart 
from pre-existing fibrosis, the strongest predictor of fibrotic 
progression in NAFLD is steatohepatitis or non-alcoholic ste-
atohepatitis (NASH). The critical features other than steatosis 
are hepatocellular degeneration (ballooning, Mallory hyaline) 
and mixed inﬂ  ammatory cell inﬁ  ltration. While much is under-
stood about the relationship of steatosis to metabolic factors 
(over-nutrition, insulin resistance, hyperglycemia, metabolic 
syndrome, hypoadiponectinemia), less is known about in-
ﬂ  ammatory recruitment, despite its importance for the per-
petuation of liver injury and ﬁ  brogenesis. In this review, we 
present evidence that liver inﬂ  ammation has prognostic sig-
niﬁ  cance in NAFLD. We then consider the origins and com-
ponents of liver inﬂ  ammation in NASH. Hepatocytes injured 
by toxic lipid molecules (lipotoxicity) play a central role in the 
recruitment of innate immunity involving Toll-like receptors 
(TLRs), Kupffer cells (KCs), lymphocytes and neutrophils and 
possibly inﬂ  ammasome. The key pro-inﬂ  ammatory signaling 
pathways in NASH are nuclear factor-kappa B (NF-κB) and 
c-Jun N-terminal kinase (JNK). The downstream effectors 
include adhesion molecules, chemokines, cytokines and the 
activation of cell death pathways leading to apoptosis. The 
upstream activators of NF-κB and JNK are more contentious 
and may depend on the experimental model used. TLRs are 
strong contenders. It remains possible that inﬂ  ammation in 
NASH originates outside the liver and in the gut microbiota 
that prime KC/TLR responses, inﬂ  amed adipose tissue and 
circulating inﬂ  ammatory cells. We brieﬂ  y review these mech-
anistic considerations and project their implications for the 
effective treatment of NASH. (Gut Liver 2012;6:149-171)
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the commonest 
form of liver disease in all regions of the world with modern 
industrialised economies, including Korea and many other 
Asian countries.
1-6 Patients usually present without symptoms 
or clinical features are non-specific. Instead, liver abnormali-
ties are found incidentally by hepatic imaging, particularly 
ultrasonography, and/or there are raised liver enzymes (alanine 
aminotransferase [ALT] and gamma-glutamyltranspeptidase).
7-9 
The diagnosis of NAFLD requires exclusion of other disorders, 
particularly viral hepatitis, significant alcohol intake, and expo-
sure to potentially hepatotoxic medications. By agreements such 
as the Asia-Pacific Guidelines on NAFLD,
6 the term NAFLD is 
now retained for cases of fatty liver associated with metabolic 
complications of over-nutrition, usually with central obesity 
and overweight. 
We and others have stressed that NAFLD is closely allied 
to pre-diabetes and metabolic syndrome.
3,10,11 As recently re-
viewed,
3 the evidence for this includes the strong risk factors 
for NAFLD posed by obesity, insulin resistance, glucose intol-
erance and one or more components of metabolic syndrome, 
and the corresponding strong risk for onset of type 2 diabetes 
and cardiovascular disease/events conferred by a fatty liver.
12-16 
Community based studies from Korea, Japan and other areas in 
North Asia have been highly informative for understanding that 
NAFLD is not so much a “Western disease” as the inevitable 
result of changes in prosperity and lifestyle that have increased 
the prevalence of overweight/obesity, insulin resistance, type 2 
diabetes and cardiovascular risk factors (clustered as metabolic 
syndrome).
3,4 Thus the community prevalence of NAFLD in 
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this region increased from less than 10% in the 1980s, through 
10% to 20% in the 1990s, to current rates of 15% to 30% or 
higher.
4,17
The known ethnic differences in metabolic complications of 
over-nutrition, such as insulin resistance, diabetes, metabolic 
syndrome and hypoadiponectinemia, are also consistent with 
the proposition that, like them, NAFLD is a genetic disorder.
3,18,19 
Thus, an encompassing concept for NAFLD pathogenesis is that 
it represents the outcome of genetically determined interactions 
between a changing environment and a susceptible host. In this 
case, the environmental factors include too much energy intake, 
particularly in the form of cheap, highly processed simple car-
bohydrates and saturated fats, and reduced levels of physical 
fitness resulting from sedentary lifestyles.
20,21 Of particular inter-
est to the present review, one prevalent genetic polymorphism 
predisposing to steatosis in overweight persons of European 
or Hispanic ancestry, PNPLA3, does not operate by increas-
ing the risks of diabetes or metabolic syndrome.
18,22-25 Instead, 
it correlates with serum ALT levels,
26 reflecting liver injury or 
inflammation, and with more severely fibrotic liver disease in 
both NAFLD/non-alcoholic steatohepatitis (NASH) and alcoholic 
cirrhosis.
27,28 This point emphasises that not all cases of NAFLD 
have the same implications for liver disease. 
NAFLD embraces a pathological spectrum of liver disease, 
from cases of steatosis with virtually no evidence of hepatocel-
lular injury or liver inflammation, often referred to as simple 
steatosis or “not NASH,” through steatohepatitis (NASH), to 
cases with cirrhosis.
29-31 The latter are often complicated by por-
tal hypertension and hepatic decompensation, and occasionally 
present with hepatocellular carcinoma (HCC).
32 At this late stage, 
steatosis and liver inflammation may both have resolved; they 
are cases of “cryptogenic cirrhosis.” As discussed next, natural 
history and clinical outcome studies based on community and 
liver clinic cohorts indicate a nearly 2-fold increase in standard-
ized mortality rates among persons with NAFLD.
33-37 Further, 
while cardiovascular disease and common cancers remain the 
two most common causes of death, liver-related mortality ranks 
the third most common, as compared to 13th in the general 
community.
36 A key question emerges: what aspects of liver pa-
thology, and what disease mechanisms, account for progression 
of NAFLD to cirrhosis and its fatal complications?
WHICH ASPECTS OF NAFLD PATHOLOGY HAVE PROG-
NOSTIC AND MANAGEMENT IMPLICATIONS 
1. Fibrotic severity
The observation that histologic characteristics are useful in 
predicting the outcome of patients with NAFLD is best exempli-
fied for patients at either end of the pathological spectrum. At 
one end, individuals with only hepatic steatosis (simple steato-
sis) infrequently show signs of any histologic progression, and 
are not at significant long-term risk of liver-related death.
33,34,38 
By contrast, those with advanced hepatic fibrosis (bridging 
fibrosis [F3] and/or cirrhosis [F4]) are likely, in time, to experi-
ence liver-related complications (ascites, variceal bleeding, and/
or HCC).
35-37 While cardiovascular disease and cancer head the 
list of causes of death, 7- to 10-year liver-related mortality (12% 
to 25%) ranks third overall.
2,36,37 In fact, the outcome of patients 
with advanced NAFLD (Child-Pugh B and C) is similar to that of 
individuals with hepatitis C virus-related cirrhosis.
35,37 
In reaching these general conclusions, certain assumptions 
are implied. First, the necessity for histologic appraisal is prob-
lematic because liver biopsies are performed less often outside 
research studies and clinical trials due to patient and clinician 
perceptions that the result will not influence management, and 
the concerns about biopsy-related complications. While non-
invasive assessment of hepatic necroinflammatory activity and 
hepatic fibrosis (serum biomarkers, transient elastography) is 
increasingly advocated,
39-44 it is most reliable at either end of the 
clinical spectrum of severity (mild, severe), when histology is 
most predictable. It remains suboptimal in the substantial num-
ber of patients in patients with mild-moderate hepatic fibrosis 
(F1, F2), among whom liver disease may progress.
34
Second, in patients with only hepatic steatosis there can be 
changes in host characteristics over time, such as increasing 
body weight or worsening insulin resistance and/or develop-
ment of diabetes, and baseline steatosis and necroinflamma-
tory severity have not been correlated with such progression of 
metabolic disease.
12,34 These considerations not withstanding, 
most gastroenterologists and hepatologist would generally re-
assure patients with isolated hepatic steatosis about their liver 
prognosis, but recommend primary care follow-up of cardio-
vascular risk factors and lifestyle interventions to address these. 
Conversely patients with advanced hepatic fibrosis should enter 
a more rigorous liver follow-up protocol. 
2. Presence of NASH (versus “not NASH”)
Current uncertainty about how “progressive’ this condition re-
ally is at least partly stems from the use of differing operational 
definitions for NASH.
45,46 Thus, NASH has been variously de-
fined to include cases with hepatic steatosis and lobular inflam-
mation (regardless of hepatic fibrosis),
29 hepatic steatosis with 
lobular inflammation and ballooning of hepatocytes with or 
without fibrosis,
33,47,48 or as separate scoring systems for “activ-
ity” (the NAFLD activity score, which assigns numerical scores 
to steatosis, lobular inflammation and ballooning and fibrosis 
(the latter usually F0-F4).
30 The Brunt system
29 was developed 
by correlating histologic changes with serum aminotransferases 
(AT) as a measure of hepatic necroinflammatory activity, and 
not with clinical outcome, whereas the scoring system proposal 
by Kleiner et al.
30 was never intended for diagnosis but was to 
be used as a tool for assessing serial liver biopsies in clinical tri-
als. The premise has been that small changes could be identified 
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descriptive remarks.
45
A head-to-head comparison of these different histologic clas-
sification systems has recently been reported,
47 and an editorial 
based on additional data from Korea reached similar conclu-
sions.
46 Both authors recommended the following. First, for rou-
tine clinical use (i.e., for diagnosis), an indication that there is or 
is not steatohepatitis is probably sufficient, with an intermediate 
category of “borderline” steatohepatitis where there is some 
uncertainity. Second, among the various components of ste-
atohepatitis, ballooning degeneration of hepatocytes is broadly 
favoured for defining NASH.
45-47 In one study, ballooning de-
generation was found to correlate with liver-related mortality, 
but only by univariate analysis.
47
In summary, the combination of hepatic fat and lobular in-
flammation is now regarded as insufficient for a diagnosis of 
NASH. However, other features such as the presence of “more 
than mild” portal inflammation,
29,33 or the presence of panacinar 
steatosis (as compared to isolated zone 3 steatosis),
48 have also 
been associated with advanced hepatic fibrosis. The latter is the 
best histologic predictor of liver-related mortality irrespective 
of the degree of steatohepatitis.
49 As expected from the earlier 
discussion, classification systems incorporating hepatic fibrosis 
in the definition of NASH correlate well with liver-related mor-
tality,
33,47 while systems that do not are not predictive of future 
outcome.
29,30 It needs to be stated, however, that the latter sys-
tems do include staging for hepatic fibrosis, but do not require 
its presence for the definition of NASH. 
3. Extent of necroinﬂ  ammatory activity
Having established that fibrotic NASH is all that matters, is 
there any value in assessing the degree of necroinflammatory 
activity? It would be if it could be determined that the grade 
of inflammation is a predictor of future hepatic fibrosis (in the 
case of liver outcomes) or metabolic syndrome-related disorders 
(in the case of overall mortality). Some evidence supports this 
view,
50 although negative studies have also been reported.
12 A 
systematic review showed clearly that age and inflammation 
on the initial biopsy (hazard ratio, 2.5) were the main indepen-
Fig. 1. Excess lipid accumulation activates inflammatory pathways and induces insulin resistance. Extracellular free fatty acids (FFA) activate toll-
like receptors (TLR), causing downstream activation of c-Jun N-terminal kinase (JNK) and IκB kinase (IKK) complex (composed of IKKα, IKKβ and 
NF-κB essential modulator [NEMO]). IKK heterotrimeric holocomplex catalyzes downstream activation of nuclear factor-kappa B (NF-κB), allow-
ing p65 (also known as RELA), a proinflammatory transcription factor, to enter the nucleus where it induces transcriptional expression of multiple 
proinflammatory chemokines (e.g., macrophage chemotactic protein 1 [MCP-1]), cytokines, and adhesion molecules (e.g., vascular cell adhesion 
molecule-1). Once activated, JNK activates c-Jun which is involved with hepatocellular cell death, and via formation of heterodimeric c-Jun:c-Fos 
forms the pro-inflammatory transcription factor, activator protein 1 (AP-1). In addition to TLR activation, some intracellular lipid molecules (Table 
2) may result in JNK/NF-κB activation by formation of reactive oxygen species (ROS); ROS may arise from excessive β-oxidation of FFA, un-
coupling of oxidative phosphorylation and mitochondrial damage caused by free cholesterol (FC) accumulation and crystallization. Alternatively, 
some intracellular lipids may induce endoplasmic reticulum (ER) stress, leading to JNK/NF-κB p65 activation (see Fig. 3 for more details). JNK ac-
tivation can also phosphorylate insulin receptor substrates (IRS)-1 and -2, which by blocking insulin receptor signal transduction leads to insulin 
resistance.
TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β.152  Gut and Liver, Vol. 6, No. 2, April 2012
dent risk factors for fibrosis progression.
51 These findings are 
not surprising because clinicians are familiar with the need to 
‘damp down’ hepatic inflammation in chronic viral hepatitis B 
or C and autoimmune hepatitis in order to achieve a favourable 
clinical outcome by preventing or reversing progression of he-
patic fibrosis. 
4. Liver histology and cardiovascular outcomes
After establishing that NASH is the hepatic component of the 
metabolic (insulin resistance) syndrome,
2,3,52,53 it was to be antic-
ipated that morbidity and mortality from cardiovascular disease 
would be highlighted in long-term studies of NAFLD. Surrogate 
markers of atherosclerosis (e.g., carotid intima-media thick-
ness) are present even in adolescents with NAFLD, and clinical 
endpoints such as deaths from myocardial infarction/need for 
coronary revascularisation have been documented in several 
natural history studies of NAFLD.
36,37 The concept that fatty liver 
may also drive the inflammatory cascade of atherosclerosis is 
now gaining acceptance. There is some evidence that individu-
als with NASH have a worse atherogenic profile,
54 and are more 
likely to have overt cardiovascular disease than patients with 
hepatic steatosis alone.
12 In summary, based on present some-
what limited evidence, it can be concluded that ongoing hepatic 
necroinflammatory activity in patients with NAFLD increases 
the risk of future cardiovascular disease, and confers a higher 
risk of unfavourable liver-related outcomes by promoting de-
velopment of hepatic fibrosis. 
WHAT ARE THE ORIGINS OF LIVER INFLAMMATION IN 
NASH? 
Inflammation is a critical response to tissue damage or infec-
tion in which secreted mediators such as cytokines, chemokines 
and eicosanoids coordinate cellular defences and tissue repair. 
Since this is generally a whole body response, it is possible that 
inflammation affecting or infiltrating the liver in NASH may 
originate outside the liver. One site of interest is the adipose, 
particularly visceral adipose which is expanded in NAFLD.
3,55,56 
Visceral adipose is inherently pro-inflammatory,
57-59 but inflam-
mation also occurs in stressed, de-differentiated subcutaneous 
adipose tissue in obesity. Important consequences include the 
release of macrophage chemokines and cytokines, notably 
macrophage chemotactic protein 1 (MCP-1) and tumor necrosis 
factor-α (TNF-α). A recent time course study showed that in 
mice fed a high fat (HF), cholesterol-enriched diet, macrophage 
and cytokine transcripts were up-regulated in adipose at 6-16 
weeks, before their appearance in liver from 16 to 26 weeks.
60 
Key inflammatory signals, including interleukin (IL)-1β, IL-1 
receptor antagonist, TNF-α and CD11b+ and CD11c+ macro-
phages, were particularly associated with liver inflammation. 
Lanthier et al.
61 have likewise shown that macrophage inflam-
mation of adipose is responsible for the early stages of both 
hepatic and peripheral insulin resistance in HF-fed mice, but 
deletion of adipose macrophages cannot reverse the later phase 
once liver inflammation is established.
In other research, a consistent increase in serum MCP-1 has 
been noted to be part of the systemic and adipose inflamma-
tory state in metabolic syndrome.
62-67 Adipocyte-derived MCP-1 
(also known as CCL-2) stimulates recruitment of chemokine (C-C 
motif) receptor 2 (CCR-2)-expressing macrophages into adipose. 
MCP-1 and its cognate receptor, CCR2, are potentially impor-
tant molecules in NASH since, like NF-κB and c-Jun N-terminal 
kinase (JNK), they unite the inflammatory response with insulin 
resistance,
68,69 as reviewed by Maher et al.
70 and depicted in Fig. 
1. MCP-1 also stimulates lipogenesis in the liver.
71 In this way, 
adipose inflammation can exacerbate steatosis and connect to 
innate inflammatory responses within the liver. 
Inflammation and de-differentiation of adipose also alters 
release of the key insulin-sensitizing and anti-inflammatory 
adipokine, adiponectin. Adiponectin blocks elaboration and 
release of TNF-α.
72,73 Serum adiponectin levels fall in metabolic 
syndrome and type 2 diabetes, while low serum adiponectin 
levels in NAFLD are inversely related to steatosis severity, and 
in some studies to the presence of NASH.
72-75 Key signalling 
pathways that explain some of the connections between hepatic 
inflammation and insulin resistance include the IκB kinases 
(IKK)/nuclear factor-kappaB (NF-κB) and JNK, as discussed later 
and reviewed.
70
In addition to macrophages recruited to inflamed adipose, cir-
culating lymphocytes and macrophages also contribute to sys-
temic inflammation in metabolic syndrome. For instance, raised 
serum cholesterol levels are associated with increased secretory 
function of circulating lymphocytes.
76 Conversely, treatment 
with simvastatin and/or ezetimibe reduced plasma levels of 
highly-sensitivity C-reactive protein and intercellular adhesion 
molecule 1. Statin or combination treatment also significantly 
reduced lymphocyte release of TNF-α, interferon-gamma (IFN-γ) 
and IL-2, an anti-inflammatory effect that was most marked for 
patients with insulin resistance.
76
Another tissue compartment that could contribute to liver in-
flammation in NASH is the gastrointestinal tract, more specifically, 
the gut microbiota. There is evidence of altered gut flora in obe-
sity,
77 and of increased mucosal permeability in NASH.
77-80 Further, 
in some animal models sterilisation of gut contents or their 
modification by probiotic administration to suppress endotoxin 
production altered liver inflammation or liver injury,
81 albeit the 
models do not conform to what we now categorize as NASH. 
The topic of intestinal-liver interactions in obesity and fatty 
liver disease has been reviewed elsewhere,
70,80,82,83 and will be 
mentioned later in respect to activation of innate immunity in 
the liver. 
Notwithstanding the potential relevance of adipose inflam-
mation,
84 circulating chemokines, cytokines and inflammatory 
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spective we will take in this review is that one may not need 
to look much further than at the liver itself to understand the 
origins of inflammation in NASH. 
LIVER CELL TYPES AND INFLAMMATION IN NASH 
The liver is comprised of several cell types, each of which 
could potentially activate or be influenced by hepatic inflam-
mation. Hepatocytes comprise 60% to 80% of all liver cells and 
conduct the metabolic, biosynthetic, detoxification and biliary 
secretory functions of the liver. In fatty liver, hepatocytes stain 
positive for triacylglycerides (TG), and in NASH the defining 
pathological element is hepatocellular injury, evident as bal-
looning, Mallory bodies and apoptosis. Among other liver cell 
types, Kupffer cells (KCs), the liver’s resident macrophage popu-
lation, natural killer (NK) cells, NK T cells, T cells, sinusoidal en-
dothelial cells (SECs) and hepatic stellate cells (HSCs) can each 
play pro-inflammatory roles.
85,86
Several possible mechanisms activate pro-inflammatory path-
ways in livers with NASH, leading to release of chemokines, cy-
tokines and other pro-inflammatory molecules, as summarised 
in Table 1. Chemokine release is particularly responsible for 
recruitment of infiltrating monocyte-derived macrophages, 
and neutrophils, which together with lymphocytes comprise 
the mixed cell type inflammatory infiltrate in NASH. Oxida-
tive stress and necrosis can provoke a neutrophil inflammatory 
response.
87 In general, pro-inflammatory signalling in NASH is 
mediated by activation of innate immune mechanisms. These 
may be primed by gut-derived endotoxin, but there is increas-
ing evidence that this is in response to lipotoxicity and/or mol-
ecules released by stressed hepatocytes (discussed below).
HEPATOCYTE STRESSES 
1. Lipotoxicity
The appearance of simple steatosis in the majority of cases 
Table 1. Some Key Pro-Inflammatory Molecules in Non-Alcoholic Steatohepatitis (NASH)
Molecule Category Activated by Actions Evidence for involvement in NASH*
IKK Protein kinase (sig-
nalling molecule)
ROS, ER stress, cytokine/
growth factor receptors, 
TLRs (Fig. 1)
Phosphorylates IκB, lead-
ing to NF-κB activation; 
can cause insulin resis-
tance
Consistent activation of NF-κB in human NASH 
and experimental models; blockade modifies 
experimental steatohepatitis
NF-κB Transcription factor 
(signalling mol-
ecule)
IKK, Myd88, ER stress (Figs 
1, 3 and 5)
Up-regulates multiple pro-
inflammatory molecules
Consistent activation in human NASH and 
all experimental models; blockade modifies 
experimental steatohepatitis (multiple studies)
JNK Protein kinase (sig-
nalling molecule)
ROS, cytokine/growth fac-
tor receptors, TLRs (Figs 
1 and 5); saturated fatty 
acids, FC, lysophosphatidyl 
choline
Mitochondrial cell death 
pathway; via AP-1 (c-
jun:c-fos) multiple pro-
inflammatory molecules; 
causes insulin resistance
Consistent activation in human NASH and all 
experimental models; blockade modifes MCD 
steatohepatitis; lowering hepatic FC abolishes 
hepatocyte JNK activation and liver inflamma-
tion/apoptosis in foz/foz mice
MCP-1 Chemokine NF-κB; may arise from 
adipose (visceral) and liver
Recruits CD11b mac-
rophages; lipogenesis 
(insulin resistance)
Circulating levels rise in multiple models. One 
of several factors that may connect metabolic 
responses (lipogenesis, insulin resistance) to 
inflammatory recruitment in NASH
CCR-2 Chemokine receptor 
(for MCP-1)
NF-κB Part of macrophage re-
cruitment
Tissue expression increased in several models
MIP-1 Chemokine NF-κB Neutrophil (PMN) recruit-
ment
Increased in experimental models
TNF-α Cytokine NF-κB, AP-1 Cytolytic (but not to NF-
κB-expressing normal 
hepatocytes); activates 
neutrophils; indirectly 
pro-fibrotic; causes insu-
lin resistance (via IKK and 
JNK); opposes adiponec-
tin secretion by adipose
Circulating levels increase in obesity but are 
similar with simple steatosis and NASH; ex-
perimental evidence conflicting (see text): no 
change in fatty liver phenotype in absence of 
TNF-α or its type 1 receptor (3 studies), but 2 
others (MCD model) found less inflammation 
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indicates that fatty livers are not necessarily pro-inflammatory. 
However, it now seems likely that the steatotic hepatocytes in 
NASH contain excess lipid molecules other than TG, and there 
is mounting evidence that such non-TG lipid molecules are 
implicated in the pathogenesis of NASH by the process of li-
potoxicity.
3,88-92 Conversely, formation of TG may actually be a 
cytoprotective mechanism in liver.
89,90 Candidate lipotoxic mol-
ecules in NASH have been reviewed;
90,92,93 they are summarized 
in Table 2.
Lipidomic analyses of human fatty livers have identified free 
cholesterol (FC) but not free fatty acids (FFA), diacylglycerides 
(DAG) or ceramide among the potential lipotoxic molecules that 
accumulate selectively in NASH but not in “not NASH’ NAFLD 
livers.
84,91,93-95 Lysophosphatidylcholine has also been implicated 
in a small study.
95 Another consistent feature is depletion of 
very long chain polyunsaturated fatty acids (PUFA); the poten-
tial relevance could be impaired production of hepatoprotective 
eicosanoids. Consistent with this proposal, the plasma lipidomic 
signature of NASH indicates over-production of proinflamma-
tory (15-hydroxyeicosatetraenoic acid) rather than anti-inflam-
matory products of lipooxygenase.
96
Some potential lipotoxic lipid species implicated in NASH 
have been explored experimentally, particularly saturated FFA 
and FC, but also (mostly in dietary studies) PUFA,
97,98 sucrose,
99 
and fructose.
100 Such studies demonstrate the unequivocal po-
tential of such lipid molecules to kill cells of hepatocyte lineage, 
by directly or indirectly activating JNK and the mitochondrial/
lysosomal cell death pathway,
101 and also to stimulate pro-
inflammatory signalling via NF-κB and JNK/activator protein 
1 (AP-1), as discussed later. In general, saturated long chain 
fatty acids (such as palmitic and stearic acids) are more toxic 
than mono-unsaturated FFA.
102-105 There are also data that the 
effects of palmitic acid may be exerted via formation of lyso-
phosphatidylcholine,
95,106 or via reactive oxygen species (ROS),
107 
or endoplasmic reticulum (ER) stress.
105 To date, however, most 
such studies have been in immortalised cell lines (typically hu-
man HCC cells) whose biology differs from well-differentiated 
hepatocytes and the intact liver (Table 2). 
Alternatively, investigators have used animal models whose 
pathology may resemble NASH but the pathogenesis does 
not involve obesity, insulin resistance and hypoadiponec-
tinemia.
108,109 For example, Marí et al.
110 have elegantly demon-
Table 1. Continued
Molecule Category Activated by Actions Evidence for involvement in NASH*
IL-1β Cytokine NF-κB, AP-1; inflamma-
some-mediated activation 
of caspase 1 (cleaves pro-
interleukin 1)
Similar to TNF-α Increased in some models; pathogenic involve-
ment less clear
IL-18, IL-33 Cytokines Often coupled to IL-1β 
reflecting inflammasome 
activation
As above
IL-6 Cytokines NF-κB, AP-1 Stat3 activation; further 
chemokine and cytokine 
release
Specific roles less clear in NASH vs not-NASH 
NAFLD
IFN-γ Cytokine  TLRs via IRFs (Fig. 5) Lymphocyte recruitment
ROS Cause oxidative 
stress
Mitochondrial uncoupling; 
lipid peroxidation (CY-
Ps2E1 and 4A); peroxi-
somes; PMNs and KCs/
macrophages
NF-κB activation via IKK; 
JNK activation; HMGB1/
TLR signalling; other ef-
fects on chemokines
Protective role of antioxidant vitamin E in some 
(not all) clinical trials and in MCD model; pro-
tective efficacy of anti-oxidant heme oxygen-
ase-1 experimentally
COX-2 Eicosanoid synthetic 
enzyme
NF-κB, AP-1; possibly 
cytokines
Synthesis of pro-inflam-
matory eicosanoids
Pathogenic role in MCD model
ICAM, 
VCAM
Adhesion molecules NF-κB, AP-1; possibly 
cytokines
Promote inflammatory 
recruitment to liver
Up-regulated in several models; pathogenic 
roles unclear
IKK, IκB kinase; ROS, reactive oxygen species; Myd88, myeloid differentiation primary response gene 88; ER, endoplasmic reticulum; TLRs, toll-
like receptors; NF-κB, nuclear factor-kappa B; JNK, c-Jun N-terminal kinase; FC, free cholesterol; AP-1, activator protein 1; MCD, methionine 
and choline deficiency; MCP-1, macrophage chemotactic protein 1; CCR-2, chemokine (C-C motif) receptor 2; MIP-1, macrophage inflammatory 
protein 1; PMN, polymorphonuclear neutrophils; TNF-α, tumor necrosis factor-α; NAFLD, non-alcoholic fatty liver disease; IFN-γ, interferon-
gamma; IRFs, interferon-regulatory factors; CYPs2E1, cytochromes P450 2E1; KCs, Kupffer cells; HMGB1, high mobility gel box 1; COX-2, cyclo-
oxygenase 2; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule. 
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strated how FC accumulates in livers of animals fed a high (2%) 
cholesterol, choline-deficient diet or high cholesterol/cholate-
supplemented diet, sensitizing hepatocytes prepared from such 
livers to apoptosis via the mitochondrial cell death pathway. In 
this work, cholesterol-loaded hepatocytes were also exquisitely 
sensitive to TNF-α-mediated cytolysis, despite unchanged NF-
κB expression, which usually confers hepatoprotection to hepa-
tocytes, unless they are depleted of reduced glutathione (GSH).
111 
Cholesterol loading appears to deplete mitochondrial GSH, ren-
dering cells susceptible to apoptosis via cytokine death receptor 
signalling (Fas or TNF-R). Such a phenomenon has also been 
demonstrated for Fas-mediated apoptosis of FC-loaded macro-
phages.
112,113
The most compelling evidence that hepatocytes may be the 
source of liver inflammation in NASH comes from studies in 
obese rodents with insulin resistance that leads to hyperin-
sulinemia and diabetes. We have used mice with a spontane-
ous mutation of the murine homology of the Alström gene 
(Alms1[termed foz/foz]),
108,114,115 while others have used wildtype 
(WT) C57B6 mice or rats.
100,116-118 Foz/foz mice exhibit hyperpha-
gia with early onset obesity and insulin resistance, the pheno-
type of Alström syndrome. Feeding them a high carbohydrate, 
HF diet with 0.2% cholesterol accelerates onset of diabetes with 
marked hypoadiponectinemia.
114 The resultant liver pathology 
shows NASH with fibrosis,
108,114,115 whereas chow-fed foz/foz 
NOD.B10 mice and WT NOD.B10 mice fed the same diet de-
velop only steatosis. Feeding WT C57B6 mice a similar HF diet, 
and particularly diets with higher cholesterol content (1% or 2%, 
often supplemented with cholic acid) also leads to unequivocal 
NASH; the onset is generally later, varying between 6 and 15 
months in different reports.
119-121 A similar approach, typically 
with cholesterol-enriched HF diet, can also produce NASH in 
some lines of rats
116,117 and in a line of opossums (ABCB4) that 
are genetically predisposed to hypercholesterolemia.
122 Finally, 
a HF diet rich in trans fats combined with high-fructose corn 
syrup equivalent and inactivity (the American Lifestyle-Induced 
Obesity Syndrome) also caused obesity-related steatosis with 
moderate necroinflammatory change, albeit in this and most 
other animal models (the foz/foz mouse is an exception), he-
patocellular ballooning, a cardinal feature of human NASH is 
inconspicuous and there was no fibrosis.
100
In HF-fed foz/foz mice, onset of NASH is associated with 
Table 2. Lipids Implicated (or Not) in Lipotoxicity to the Liver and Hepatocytes
Lipid type*
Accumulation discriminates NASH from
“not NASH” liver pathology
Comments: evidence of liver lipotoxicity
TG No (clinical samples, experimental 
models)
Does not cause tissue injury or inflammation/fibrosis; TG formation 
may be protective; role in hepatic insulin resistance controversial
DAG No (fewer data) Potential pro-inflammatory pathway (via protein kinase C activation); 
favoured role in mediating insulin resistance
FFA (long chain), saturated No (clinical samples, lipidomic readouts 
of experimental models)
Palmitic acid activates JNK and causes lipoapoptosis in HCC cells and 
primary hepatocytes, possibly via formation of lysophosphatidyl-
choline or ROS; in some animal models, saturated (or trans) fat in 
diet worsens insulin resistance and liver pathology; blockade of TG 
formation causes FFA accumulation and worse inflammation/fibrosis
FC Yes (2 human studies; several meta-
bolic syndrome models in mice, rats 
and opossum)
Yes; activates JNK, at least in macrophages; depletes mitochondrial 
GSH rendering hepatocytes susceptible to TNF-α or Fas-mediated 
cell death
Total cholesterol (mostly CE) Less clear-cut differences Formation of CEs may play similar role as TG formation, countering 
lipotoxic effects of FC and FFA (but this has not been demonstrated 
experimentally)
Ceramide No (several studies) Favoured role in some neurotoxicities, but no evidence for role in 
liver lipotoxicity
Lysophosphatidyl choline Unclear (one small study with little 
information on disease phenotype)
Causes lipoapoptosis to primary hepatocytes/HCC cell lines (and see 
palmitic acid)
Other: e.g., mono-acylglycer-
ides, long chain FA CoA esters
No (few informative data) Potential implication as mediating insulin resistance
NASH, non-alcoholic steatohepatitis; TG, triglyceride; DAG, di-acylglycerides; FFA, free fatty acids; JNK, c-Jun N-terminal kinase; HCC, hepato-
cellular carcinoma; ROS, reactive oxygen species; TG, triacylglycerides; FC, free cholesterol; GSH, glutathione; TNF-α, tumor necrosis factor-α; 
CE, cholesterol ester; FA, fatty acyl.
*for further comments and references, please refer to the text.156  Gut and Liver, Vol. 6, No. 2, April 2012
more than 200-fold increase in liver cholesterol esters (CE), and 
~8-fold increase in FC.
115 Removal of cholesterol from the HF 
diet reduces hepatic CE and FC content and ameliorates the 
severity of liver injury and steatohepatitis.
115 Likewise, pharma-
cological treatments that lowered hepatic cholesterol dampened 
necroinflammatory severity in this NASH model.
123 Conversely, 
increasing dietary cholesterol (to 2% in foz/foz mice,
115 or 1% in 
other studies with C57B6 mice
108-121) worsens inflammation and 
liver injury in experimental NASH. It is plausible that FC or oth-
er cholesterol fractions (7-ketocholesterol and other oxysterols 
are candidates) could activate KCs and recruited macrophages 
directly, analogous to processes implicated in atheroma,
112,113,124 
and demonstrated in low density lipoprotein receptor knockout 
and apoE knock-in mice.
125,126 However, immunofluorescence 
studies in foz/foz mice (unpublished data) and human livers
94 
show that hepatocytes are the cell type most conspicuously lad-
en with FC in NASH. The subcellular compartments involved are 
the plasma membrane, ER and mitochondria.
94,115 A noteworthy 
feature of our studies has been the location of macrophages and 
neutrophils around heavily lipid-laden and swollen hepatocytes, 
some of which are ballooned (Fig. 2). Cellular processes could 
lead hepatocytes to incite inflammatory recruitment in NASH 
are discussed next. 
2. Cytokines and oxidative stress
An earlier concept of NASH pathogenesis envisaged a “two 
hit” process, in which the abnormal metabolic milieu causing 
steatosis comprised the “first hit,” and the vulnerability of a 
fatty liver to a separate injurious process (“second hit”) resulted 
in cell death and inflammation.
127 Fifteen years ago, the injuri-
ous processes of interest were oxidative stress and cytokines, 
particularly those stimulated by endotoxin (lipopolysaccharides), 
such as TNF-α.
128,129 While both oxidative stress and cytokines 
are clearly evident in livers with NASH,
130-133 the weight of 
evidence is that TNF-α is a consequence rather than cause of 
liver inflammation in NASH.
2,72,134 Further, serum TNF-α levels 
increase in obese people, most likely originating from macro-
phages in the inflamed adipose;
84 importantly, values in NAFLD 
patients do not discriminate NASH from “not NASH.”
74 It is also 
salient that some experimental forms of steatohepatitis, includ-
ing a forced over-nutrition model,
135 can occur in the absence of 
TNF-α or its NF-κB signalling type 1 receptor.
136,137
Oxidative stress is a key pro-inflammatory pathway in acute 
liver injury, such as ischemia-reperfusion injury
87 and in some 
types of steatohepatitis,
134 including alcohol-related liver disease, 
methionine deficiency,
138 and methionine and choline deficient 
(MCD).
137,139-142 Older studies employing immunohistochemistry 
demonstrated evidence of oxidized proteins, lipids and DNA in 
NASH livers,
143-145 but this could be a consequence of inflam-
mation rather than its cause. A potential distraction has been 
identification of multiple sources of pro-oxidants in NASH, such 
as mitochondria (from uncoupling of oxidative phosphoryla-
tion to release reactive oxygen species), from ER (induction of 
cytochromes P450 [CYP] 2E1 and 4A),
146,147 peroxisomes
89 and 
inflammatory cells (NADPH oxidase).
134,148,149 Hepatoprotection 
from anti-oxidants and anti-oxidant pathways (such as heme 
oxygenase) has been demonstrated in MCD steatohepatitis,
150,151 
and vitamin E may have some efficacy against necro-inflamma-
tory change in NASH,
152 but there is less evidence for operation 
of oxidative stress in murine models that link metabolic syn-
drome to NASH. We agree with the interim conclusion reached 
by several experts,
89,91 that oxidative stress and/or cytokines are 
not likely to be the initiators of liver inflammation in NASH, al-
though roles in insulin resistance, perpetuation of necroinflam-
matory change, fibrogenesis and progression towards cirrhosis 
and hepatocarcinogenesis remain likely.
3. ER stress
Accumulation of unfolded proteins within the ER is often 
observed in cells like hepatocytes that have high rates of protein 
synthesis. The cellular responses, collectively known as the un-
folded protein response (UPR), involve provision of chaperones, 
Fig. 2. Inflammatory cell recruitment and localization around lipid-laden hepatocytes in HF-fed foz/foz mice with non-alcoholic steatohepatitis 
(NASH). (A) H&E-stained liver section from HF-fed (0.2% cholesterol) foz/foz mouse with NASH, showing several enlarged hepatocytes with mac-
rosteatotic vacuoles, and at least one ballooned hepatocyte (bottom right). (B) Macrophages (F4/80 positive), and (C) neutrophils (myeloperoxidase 
positive) accumulate around hepatocytes showing macrosteatotic vacuoles. These livers contain large amounts of free cholesterol.
115 Scale bars 
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such as 78 kDa glucose-regulated protein (GRP78), for protein 
refolding and transport out of the ER, and suppression of further 
protein synthesis.
153-155 Failure to mount an adequate UPR trig-
gers a set of intracellular molecular “switches” that comprise the 
ER stress response. The three key pathways are depicted in Fig. 
3. Through these pathways, ER stress activates NF-κB, JNK and 
C/EBP, with downstream effects on inflammatory recruitment, 
phosphorylation of insulin receptor signalling intermediates 
(to worsen insulin resistance), lipogenesis, and oxidative stress. 
These processes can ultimately lead to dismantling of the cell 
by apoptosis, particularly involving C/EBP-homologous protein, 
which transcriptionally suppresses anti-apoptotic Bcl-2 and in-
duces pro-apoptotic Bim (Fig. 3).  
Relationships between hepatic ER stress, lipogenesis, insulin 
resistance and hepatic steatosis in obesity and metabolic syn-
drome have been the subject of intense scrutiny,
155,156 and ER 
stress has been proposed as a mechanism in diverse experimen-
tal forms of liver injury (alcohol-related, drug-induced).
154-157 In 
obese humans, UPR (typically GRP78 expression) and ER stress 
markers have been noted in the adipose, liver and pancreatic 
beta cells.
158 To date, however, the evidence for operation of he-
patic ER stress in human NAFLD/NASH is limited and inconsis-
tent; some pathways seem to be activated, others are not,
159 and 
there have not been informative correlations between pathways 
and disease phenotype. Likewise, the evidence for operation of 
ER stress in animal models is conflicting.
155,160-163 In particular, 
there is little evidence that ER stress is a pro-inflammatory 
pathway in models that exhibit both the metabolic determinants 
of NAFLD and steatohepatitis pathology, such as HF-fed foz/foz 
mice (van Rooyen, unpublished data).
Impaired activity of sarcoplasmic-ER calcium ATPase-2b 
(SERCA), the ER calcium sequestering pathway, appears to be a 
key mediator of cellular responses to ER stress.
164 Such inhibi-
tion could deplete ER calcium stores, causing cytoplasmic ionic 
calcium concentrations to rise, increasing its movement into 
mitochondria with implications for mitochondrial injury, but 
this has not yet been demonstrated. Enrichment of the ER mem-
brane with cholesterol also inhibits SERCA activity in parallel 
Fig. 3. Mammalian unfolded protein response (UPR) pathways. The UPR is triggered by several events, including protein unfolding/misfolding, 
hypoxia, low adenosine triphosphate levels, ER calcium depletion, and protein/sterol over-expression, causing dissociation of 78 kDa glucose-
regulated protein (GRP78) from the three UPR sensors, (A) inositol-requiring enzyme 1α (IRE1α), (B) protein kinase RNA-like endoplasmic reticu-
lum kinase (PERK), and (C) activating transcription factor-6 (ATF6). Activated IRE1α undergoes dimerization and autophosphorylation to generate 
endogenous RNase activity; in turn, this is responsible for splice truncation of X-box binding protein 1 (XBP1S) mRNA. Additionally, IRE1α may 
also activate the extrinsic apoptosis pathway, in which tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2)-dependent downstream 
activation of c-Jun N-terminal kinase (JNK) and caspase-12 takes place. Once activated, PERK undergoes homodimerisation and autophosphory-
lation to activate eukaryotic translation initiation factor 2 (eIF2α). In turn, this induces ATF4 expression. Separately, dissociation of GRP78, allows 
ATF6 processing by the Golgi complex, where proteases S1P and S2P cleave an active 50 kDa (p50) ATF6 domain that is free to translocate to the 
nucleus. Xbp1s, ATF4 and ATF6, as well as other unlisted factors, are responsible for three dominant cell responses to UPR. The folding pathway 
induces increased expression of molecular chaperones, including GRP78, assisting in compensatory ER protein folding. Alternatively, the cell may 
respond by increasing ER-associated protein degradation (ERAD) pathway, whereby gene products target and degrade unfolded proteins in the ER. 
Prolonged UPR results in the activation of the intrinsic apoptosis pathway; this ATF6 and ATF4-dependent process induces C/EBP-homologous 
protein (CHOP) expression. In turn, CHOP inhibits B-cell lymphoma 2 and induces apoptosis.158  Gut and Liver, Vol. 6, No. 2, April 2012
with increased membrane order parameter.
155 This has potential 
implications for NASH because ER is one site of increased cho-
lesterol deposits (van Rooyen, unpublished data). Ultimately, the 
mechanistic relevance of ER stress as a disease pathway must 
come from in vivo studies of chemical chaperones that block its 
operation.
165 One such chaperone is tauroursodeoxycholic acid, 
an agent that appears to have little if any therapeutic efficacy 
against NASH.
166,167 
4. Mitochondria, autophagy and the regulation of inflam-
mation
Ultrastructural studies have consistently shown intra-
mitochondrial crystals in NASH, the identity of which has not 
been resolved,
168,169 and the association with decreased hepatic 
adenosine triphosphate (ATP) levels is also consistent with 
mitochondrial uncoupling or injury.
170,171 Mitochondria are a 
major source of ROS. Physiologically, about 2% of oxidative 
phosphorylation is uncoupled, but during hibernation, obesity 
and in several experimental models of NAFLD expression of un-
coupling proteins (UCP), particularly UCP2, increases.
172,173 Dam-
age to mitochondrial DNA and proteins, saturated FFAs and 
excessive ionic calcium could further uncouple oxidative phos-
phorylation, thereby generating oxidative stress. As mentioned 
earlier, FC impairs GSH uptake into mitochondria with similar 
deleterious effects.
110,174 In addition, permeabilization of the in-
ner mitochondrial membrane by opening of the mitochondrial 
permeability transition pore is a key pathway to initiation of 
cell death by apoptosis or necrosis.
175
A critical cellular response to mitochondrial injury or starva-
tion (energy depletion) is autophagy (termed mitophagy when 
confined to mitochondria).
176-179 During mitophagy, damaged 
mitochondria are eliminated in a controlled process of lysosom-
al membrane and macromolecular turnover. This counters cel-
lular degeneration and prevents unnecessary cell loss or, in the 
face of insurmountable damage, prepares residual cellular rem-
nants (apoptotic bodies) for macrophage-mediated clearance in 
the more organised cell death pathway of apoptosis.
176 By aug-
menting apoptosis, autophagy tends to dampen inflammation, 
whereas necrotic cell death can promote it.
87,178-180 Mitochondria 
play a central role in inflammatory pathways, such as NF-κB 
Fig. 4. Mitophagy inhibits pathways of mitochondrial dysfunction and associated cell death and inflammation. Mitophagy restitutes physiologi-
cal cell functioning by inhibiting mitochondrial-related cell death and/or injury arising either from the generation of reactive oxygen-species 
(ROS) or pro-inflammatory signals, or as a result of mitochondrial membrane permeability transition (MPT). During activation of the intrinsic 
apoptosis pathway, BH3-only protein members, including BAK and BAX, effect mitochondrial membrane permeabilisation (MOMP) and release 
of intermembrane space proteins, including cytochrome c which induces a downstream caspase cascade activation that leads to apoptosis. Alter-
natively, necrotic cell death may be initiated by cyclophilin D-dependent initiation of MPT pore. Once opened, MPT destroys the mitochondrial 
transmembrane potential (ΔΨm), thereby abrogating oxidative phosphorylation and exacerbating ROS generation. Excessive ROS formation can 
activate the NACHT, LRR and PYD domains-containing protein 3 (NALP3) inflammasome. Uncoupling of oxidative phosphorylation can also 
trigger MPT, during which mtDNA may undergo cytoplasmic translocation, leading to nuclear factor-kappa B (NF-κB) and interferon regulatory 
factor-dependent inflammatory pathway activation. Importantly, excess intra-mitochondrial ROS is able to mutate mitochondrial DNA (mtDNA), 
leading to premature aging and mitochondrial inefficiency post-replication (this in turn exacerbates ROS generation through impaired oxidative 
phosphorylation).Farrell GC, et al: NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications  159
and interferon-responsive factors (IRF), as depicted in Fig. 4, as 
well in the induction of inflammasomes (discussed below). There 
is also an interaction between impairment of autophagy and in-
duction of ER stress.
181 The recent interest in whether abrogation 
of autophagy contributes to inflammatory recruitment in NASH 
has been reviewed.
179
5. The inﬂ  ammasome
The inflammasome is a larger multimeric structure that regu-
lates caspase 1 activation.
182,183 The NLRP3 (nucleotide-binding 
domain, leucine-rich repeat containing) inflammasome (also 
known as cryopyrin or NALP-3) is expressed by myeloid cells 
and is up-regulated by pathogen-associated molecular patterns 
(PAMPs). It requires a caspase recruitment domain, and can re-
cruit pro-caspase 1 in the presence of the adapter protein ASC 
(apoptosis-associated speck-like CRD-domain containing pro-
tein). Once all the components of the NALP3 inflammasome are 
assembled in the cytosol, caspase 1 is released and can promote 
the cleavage and therefore maturation of pro-inflammatory 
cytokines (pro-IL-1β, pro-IL-18, and IL33) to promote and sus-
tain inflammation. NLRP3 inflammasome can be activated by 
several endogenous and exogenous agonists, as reviewed else-
where.
182,183 Salient to NASH, palmitic acid (but not oleic acid) 
induces activation of the NLRP3-ASC inflammasome to activate 
caspase 1 and cause IL-1β and IL-18 production.
183 This path-
way involves mitochondrial production of ROS (Fig. 4). Other 
agonists that could be relevant include uric acid crystals, which 
can precipitate in the extracellular space of dying cells, and ex-
tracellular DNA, possibly including mitochondrial DNA. 
The inflammasome is activated in experimental alcohol-
induced liver injury,
83 and in mice fed the MCD diet, but not in 
HF diet-induced simple steatosis.
184 Csak et al.
184 exposed hepa-
tocyte cultures to palmitic acid, and showed that this sensitised 
liver cells to release IL-1β following the further addition of lipo-
polysaccharide. In addition, palmitic acid provoked hepatocytes 
to release undefined “danger signals,” which then activated the 
inflammasome in liver lymphocytes and macrophages to aug-
ment release of IL-1β and TNF-α. Other work has confirmed 
that, under certain circumstances, hepatocytes can themselves 
secrete chemokines and cytokines.
185 Thus, activation of the 
inflammasome is one of several models by which hepatocytes 
could play a central role in inflammatory recruitment in NASH, 
but as indicated next, there are other potential pathways.
6. Ballooned hepatocytes and inﬂ  ammatory recruitment; is 
the p53/senescence pathway involved? 
Early studies identified ballooning as one of few histologi-
cal features associated with risk of cirrhosis development in 
NAFLD.
33 While not always confirmed by subsequent studies, 
in which presence of fibrosis and histology as “definite NASH” 
tend to over-ride ballooning in multivariate analyses,
12,47 a link 
between ballooning and portal fibrosis has been emphasized by 
Richardson et al.
186 These authors also found a strong link be-
tween ballooning and lobular inflammation in NASH, which is 
consistent with the proposal that ballooning attracts inflamma-
tory cells, as indicated by their co-localisation in experimental 
studies (Fig. 2), and their implication in secretion of Hedgehog 
ligands.
187-189 This family of fibrogenic transcription factors also 
plays a pro-inflammatory as well as pro-fibrotic role. Thus bal-
looned hepatocytes have been shown to be a focus for both HSC 
activation and hepatic precursor cell recruitment, both of which 
are under cytokine regulatory control.
189
Ballooned hepatocytes often contain Mallory’s hyaline 
(also known as Mallory-Denk bodies), which are derived from 
ubiquitin-modified intermediate (cytokeratin [CK]) filaments; 
ubiquitin staining can be used to identify ballooned cells more 
clearly.
190-193 This destruction of intermediate filaments might 
indicate that cytoskeletal disruption leads to ballooning, but 
ultrastructural studies are limited. There is also evidence that 
foamy, lipid micro-droplets confer the glazed appearance of bal-
looned hepatocytes rather than hydropic change.
190,192,193 Apop-
tosis is increased in livers with steatohepatitis,
101,104,132,193 while 
circulating peptides liberated by caspase 3 cleavage of CK18, an 
hepatocyte-specific CK, serves as a biomarker for NASH versus 
“not NASH.”
194,195 The original term for apoptosis was “shrinkage 
necrosis”; therefore, the presence of ballooning seems more like-
ly to reflect imminent cell necrosis rather than apoptosis. If so, 
the disintegration products could be pro-inflammatory, and it is 
well recognized that necrosis, an unregulated form of cell death, 
activates macrophages, neutrophils (e.g., by high mobility gel 
box 1 [HMGB1]) and other pro-inflammatory pathways,
87,180,196 
including the inflammasome discussed earlier. 
An alternative possibility is that ballooned hepatocytes are 
a reflection of cellular senescence in the liver. In epithelial 
cells, stressors such as oxidative stress and DNA damage can 
lead to replicative senescence.
196 In humans, this is particularly 
associated with shortened telomere length such that cell divi-
sion is no longer possible.
197 Most interest in senescence as a 
disease mechanism has been for neurodegenerative disorders 
and cancer;
196,197 it does not appear to have been much studied 
in NASH. However, cirrhosis is associated with loss of telomere 
length,
198 and p53, the guardian of senescence,
196,199 is up-regu-
lated in several types of fatty liver disease.
200 Senescence arrests 
cell division by inducing cell cycle inhibitors (p21, p16
INK4A, Rb) 
and has a characteristic molecular expression profile closely 
linked to regulation of an inflammatory response in neighbour-
ing tissues.
197 The pro-inflammatory molecules involved include 
cytokines (IL-1, IL-6, IL-8), chemokines (IL-8, MCP-1, GRO α/
β/γ) and chemokine receptors (CXCR2), most of which are con-
sistently found to be up-regulated in experimental NASH (Table 
1).
72,86,132,137,201 Further research is required to establish whether 
hepatocyte senescence is inherent to inflammatory recruitment 
in the transition of steatosis to NASH.160  Gut and Liver, Vol. 6, No. 2, April 2012
PRO-INFLAMMATORY SIGNALS 
A common outcome of the above subcellular stress processes 
is the activation of intracellular pathways that signal pro-
inflammatory responses. These signalling pathways include 
ionic calcium, protein kinase and transcription factor activation, 
and the most consistent are activation of NF-κB and JNK. These 
pathways will now be considered separately, but it should be 
noted that they are usually activated in tandem and often co-
regulate the same gene products.
1. Activation of NF-κB
NF-κB is a transcription factor comprised of five peptides 
that form homodimeric or heterodimeric complexes; p65 and 
p50 are highly expressed in liver. NF-κB p65:p50 heterodimers 
regulate the transcription of several hundred pro-inflammatory 
molecules (p50:p50 tends to be inhibitory), including cytokines, 
chemokines, adhesion molecules, nitric oxide and cyclooxygen-
ase 2.
141 In resting (G0) hepatocytes, NF-κB is sequestered in the 
cytosol bound to inhibitory (IκB) proteins. Their phosphoryla-
tion, mediated by IKK, and subsequent ubiquitination targets 
the NF-κB -IκB complex to the 26S proteasome for degradation. 
This liberates NF-κB in a form that can be transported into the 
nucleus. Detection of p65 in nuclear extracts, or binding to cog-
nate oligonucleotides in gel shift assays serve as indicators of 
NF-κB activation, together with increased levels of transcripts 
for “NF-κB-responsive genes.” IKK is activated directly by oxi-
dative stress and other cellular stressors (such as ER stress), or 
via liganding of NF-κB-signaling receptors.
NF-κB activation is uniformly found in human NASH
202 and 
in all animal models in which it has been studied. Using MCD 
fed mice, we employed TNF-α and TNF-R1 knockout animals, 
and in vivo transfection of WT mice with non-degradable 
mutant-IκB to show that NF-κB activation is essential for he-
patic inflammatory recruitment in steatohepatitis;
137 further, 
such NF-κB activation occurs independently of TNF-α. Other 
work using the MCD dietary model has produced conflicting 
findings; curcumin, which blocks oxidative stress-mediated 
NF-κB activation provided protection,
203 but TNF-α anti-serum 
reduced liver injury in rats administered the MCD diet,
204 while 
Tomita et al.
205 found that TNF-R knockout mice had protection 
against liver fibrosis in their MCD experiments. 
Fractionation of livers from HF-fed foz/foz mice (Larter, unpub-
lished data) and MCD-fed animals
137 shows that NF-κB activation 
is most prominent in non-parenchymal cells (KCs, SECs, HSCs), 
but it is also evident in hepatocytes.
137,206 The emerging concepts 
of metabolic stress mentioned earlier provide some indication that 
pro-inflammatory pathways in NASH could eminate from stressed 
hepatocytes via activation of NF-κB. Alternatively, TNF-α, IL-1β 
and other cytokines released from NF-κB-activated KCs could acti-
vate NF-κB in neighbouring hepatocytes.
Myeloid differentiation primary response gene 88 (Myd88) 
null mice are refractory to dietary steatohepatitis caused by a 
choline deficient and defined amino acid (CDAA) diet.
207 Using 
bone marrow chimeric (WT/Myd88
-/-) mice, Miura and col-
leagues showed that the KC compartment was essential for in-
flammatory recruitment in this model.
207 Further, the upstream 
stimulus to Myd88/NF-κB activation appeared to be Toll-like 
receptor 9 (TLR9),
207 located in endosomes/lysosomes and most 
responsive to unmethylated CpG-containing DNA. The implica-
tion of TLRs and their role in the innate immune response and 
activation of NF-κB in NASH is discussed later. 
2. JNK
Like NF-κB, the JNKs (1 and 2) can be activated directly by 
oxidative stress and by lipotoxic molecules (FFA, FC), or as the 
result of ligand binding to growth factor and TNF superfamily 
death-signalling receptors (Fas, TNF-R1, TNF-related apoptosis-
inducing ligand death receptors) or TLRs.
208 JNK activates the 
mitochondrial apoptosis pathway and forms the c-jun:c-fos het-
erodimer, AP-1; AP-1 is pro-inflammatory, typically inducing 
similar genes as NF-κB.
JNK appears always to be activated in lipotoxicity and in 
both experimental and human forms of NASH.
159,209-213 In semi-
nal work, Schattenberg et al.
209 showed that activation of JNK1 
(but not JNK2) was essential for inflammatory recruitment in 
MCD-induced steatohepatitis; others have confirmed this.
210-212 
Saturated fatty acids activate JNK in primary hepatocytes and 
tumour cells of hepatocyte lineage;
95,101,106,214 and this was a 
critical pathway to cell death by the mitochondrial apoptosis 
pathway.
101,214
In the foz/foz diabetes/metabolic syndrome model, we have 
noted that both JNK1 and JNK2 are activated with NASH, but 
not in genotype or dietary controls with simple steatosis.
212 Fur-
ther, dietary or pharmacological measures that lowered hepatic 
FC virtually abrogated JNK activation in association with miti-
gation of liver injury (ALT elevation), hepatocyte apoptosis and 
macrophage accumulation.
123 These observations are consistent 
with the proposal that JNK activation is a key injury and in-
flammatory pathway in metabolic syndrome-related NASH.
INNATE IMMUNITY IN NAFLD: TLRS, KCS AND LYMPHO-
CYTES
There is little doubt that innate immunity is involved in the 
inflammatory response in NASH, and this topic has been re-
viewed elsewhere.
70,82,83,85,208 Only the most salient aspects will be 
mentioned here.
1. Why could innate immunity be relevant to inﬂ  ammation 
in NASH? 
As mentioned, necrotic cell death elicits an inflammatory 
response. This concept was refined in 1994 when Matzinger
215 
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nate immune system can respond to key molecules released by 
damaged cells, thereby eliminating them. The mechanism by 
which stressed or dead cells trigger inflammation and adaptive 
immune responses involves damage-associated molecular pat-
terns (DAMPS),
180,216-218 also termed alarmins. Intracellular pro-
inflammatory DAMPS include high-mobility group gel box 1 
(HMGB1),
218 heat shock proteins, fibrinogen and fibrinonectin, 
and mitochondrial products such as formyl peptides and mi-
tochondrial DNA.
217 Although they differ from PAMPs, some 
DAMPS can be recognised by similar receptors, particularly 
TLRs (e.g., TLR4 responds to both HMGB1 and lipopolysaccha-
ride).
217,219 
2. TLRs and NASH
Eight TLRs are expressed in mammalian liver (TLRs 1, 2, 4, 
6-10), with varying levels of expression on KCs, hepatocytes, 
SECs and HSCs.
85 Most are expressed on the cell surface, but 
TLRs 1, 3 and 9 are intracellular (endosomal/lysosomal) pro-
teins. TLRs recognise molecular patterns present on a broad 
range of pathogens and altered or specialised host molecules. 
Upon ligand binding and with recruitment of certain co-factors 
(e.g., myeloid differentiation factor 2 [MD2]), they signal via 
overlapping protein casettes to trigger inflammatory and antivi-
ral responses, as well as maturation of dendritic cells to activate 
adaptive immunity.
216 Individual TLRs interact with different 
combinations of adapter proteins (e.g., MD2) and activate tran-
scription factors such as NF-κB, AP-1 (via JNK) and interferon-
responsive factors (IRF). As shown in Fig. 5, MyD88 is shared 
by almost all TLRs and recruits members of the IL-1 receptor-
associated kinase family. In fact, the intracellular domain of 
Fig. 5. Toll-like receptor (TLR) signalling involves JNK and NF-κB p65 activation. Toll-like receptors (TLR) constitute a family of receptors in-
volved in pro-inflammatory signalling in the innate immune system, responsible for the recognition of pathogen-associated molecular patterns 
(PAMPs) and exogenous stimuli, such as pathogens, or endogenous agonists, such as sterile tissue damage; the later are termed danger-associated 
molecular patterns (DAMPs). Of the 9 known TLR receptors, four (TLR-3, -7, -8, and -9) are expressed on the endosomal membrane and are re-
sponsible for viral particle surveillance, including detection of deoxy-cytidylate-phosphate-deoxy-guanylate DNA (CpG-DNA), and single- and 
double-stranded RNA. The remaining TLRs are expressed on the plasma membrane and are responsible for the detection of extracellular microbial 
pathogens. Relevant PAMPs include: LPS, diacyl- and triacyl lipopeptides, and flagellin, as well as several DAMPs, including HMGB1. Activated 
TLR3, as well as TLR4, signal through adaptor protein TIR-domain-containing adapter-inducing interferon-β (TRIF), which in turn recruits RIP1 
to activate the IKK complex, thereby activating nuclear factor-kappa B (NF-κB). The other TLRs signal through toll/interleukin-1 receptor domain 
containing adaptor protein (TIRAP) and myeloid differentiation factor 88 (Myd88). Activated Myd88 induces the recruitment of IL-1R-associated 
kinase (IRAK) 4, as well as IRAK1, which bind TRAF-6 and transforming growth factor-β activated kinase (TAK)-1. IRF5 and IRF7 are then re-
cruited to the post-Myd88 protein complex. Interferon-regulatory factor 7 (IRF7) recruitment is dependent upon on TLR7 and TLR9 signalling. The 
IRAK1/4/TRAF6/TAK1/IRF5/7 complex is responsible for downstream Myd88-dependent activation of c-Jun N-terminal kinase (JNK) and NF-κB. 
TRAF, tumor necrosis factor (TNF) receptor-associated factor; MEKK, MAP kinase kinase kinase; MKK, mitogen-activated protein kinase kinase; 
ASK, apoptosis signal-regulating kinase.162  Gut and Liver, Vol. 6, No. 2, April 2012
plasma membrane expressed TLRs exhibits IL-1 receptor motifs, 
and their intracellular signalling shares several intracellular adapter 
molecules with IL-1 (Fig. 5).
When released from necrotic cells, HMGB1 stimulates KCs 
and monocytes to produce pro-inflammatory mediators by act-
ing as an endogenous ligand for TLR4, although it might do 
that by forming highly inflammatory complexes with other 
molecules (ssDNA, endotoxin, IL-1β, nucleosomes).
218 TLR4 is 
involved in acute liver injury, such as hepatic ischemia-reperfu-
sion injury,
220-222 in alcoholic liver injury (when priming by gut-
derived endotoxin is pivotal).
82 and is also up-regulated in MCD 
steatohepatitis
219,223 and fructose-induced hepatic steatosis (not 
NASH).
224,225 Saturated FFA can also bind to TLR4.
70,90,226-228 TLR4 
and MD2, its co-receptor for endotoxin, are expressed on KCs, 
hepatocytes and HSCs. Deletion of either TLR4 or MD2 dampens 
(but does not abolish) necroinflammatory activity of MCD ste-
atohepatitis, with the most impressive effects being on NADPH 
oxidase expression and activation of inflammatory cells.
229
Other research has identified activation of TLRs2 and 9 in var-
ious experimental models of NAFLD or NASH.
225 As mentioned 
earlier, TLR9 is located within the cell and is most responsive to 
unmethylated CpG-containing DNA, but it also binds HMGB1. 
TLR9-deficient mice are protected from steatohepatitis in the 
CDAA model.
207 TLR2 (but not TLR4) expression by hepatocytes 
can be induced by lipopolysaccharide, TNF-α and IL-1β via NF-
κB activation, while signalling cross-talk between TLR4 and 
TLR9 amplifies the inflammatory response of macrophages,
230 
indicating other potential loops for perpetuation of inflamma-
tion in NASH. TLR5 is not expressed in the liver, but it has re-
cently been reported that TLR5 knockouts have altered gut flora 
and develop obesity and metabolic syndrome, including insulin 
resistance and steatosis.
231 Any relevance to NASH has yet to 
be established, although a fascinating finding was that transfer 
of the altered gut flora from TLR5
-/- mice to healthy animals 
resulted in a similar disease phenotype, including (non-inflamed) 
fatty liver.
231
3. Kupffer cells
KCs are specialised tissue macrophages in the liver. They 
not only contribute to insulin resistance in fatty liver disease,
61 
but unite the inflammatory responses in many liver diseases.
232 
KCs are particularly sensitive to gut-derived endotoxin, acting 
through CD14, TLRs 2 and 4 and adapter proteins such as MD2 
to activate NF-κB via MyD88.
70,229 Other intracellular signalling 
molecules lead to induction of IFN-γ, which is important for 
lymphocyte recruitment.
86,208 In chimeric mice with KCs derived 
from MyD88
-/- bone marrow donors,
207 there was amelioration 
of the inflammation and fibrosis induced in the CDAA model 
of steatohepatitis compared with WT mice, demonstrating a 
key role for KC activation in this model. To the authors’ minds, 
the data are more convincing than those in a recent study (us-
ing an irradiated, 2% cholesterol HF diet that is hepatotoxic) in 
which the authors proposed that TLR4 on hepatocytes, not KCs, 
responds to HMGB1 by NF-κB activation.
206 Other earlier work 
showed that engulfment of cellular fragments denoted as apop-
totic bodies from UV-treated murine hepatocytes (which would 
also causes oxidative stress) activated KCs to generate FasL and 
TNF-α.
233 Ablation of KCs (e.g., by gadolinium or clodronate 
liposomes) reduces severity of liver injury and inflammation 
in alcohol-related liver injury in rodents, as does measures to 
change the gut flora in favour of non-endotoxin producing or-
ganisms. In a HF-fed mouse model, KC ablation ameliorated se-
verity of steatosis by releasing hepatocytes from IL-1β and NF-
κB-dependent suppression of peroxisome proliferator-activated 
receptor (PPAR)-α activity, thereby allowing PPAR-γ to exert its 
effects on fatty acid oxidation.
234 
4. Lymphocytes
Several types of lymphocytes are present in the normal liver, 
including NK cells, NK T cells, and T cells.
86 Hepatic NK cells 
can be regulated by KC-derived cytokines (IL-1, IL-18), and in 
turn generate IFN-γ which participates directly in cell killing 
and in modulation of T cell responses. Lymphocytes accumulate 
in NASH livers, but which subpopulations predominate and 
their pathogenic roles in injury and inflammation have not yet 
been fully characterized.
5. Neutrophils
The presence of neutrophils (polymorphonuclear neutrophils, 
[PMNs]) among the liver inflammatory infiltrate of alcoholic 
steatohepatitis has long been recognized. Neutrophils are also 
present in NASH,
29,31 where their possible pathogenic signifi-
cance remains obscure. In the foz/foz metabolic syndrome 
model of NASH, the reduction of hepatic cholesterol stores 
which ameliorates liver injury, apoptosis and macrophage re-
cruitment does not appear to alter accumulation of myeloper-
oxidase positive cells (PMNs) (van Rooyen, unpublished data). 
On the other hand, reduction of hepatic triglyceride stores and 
lipogenesis either by a dietary reversion strategy or with Wy-
14,643 (a potent PPAR-α) agonist, has more impressive effects 
on neutrophils than on macrophages.
212 Dietary reversion (from 
HF to chow) suppressed UCP2 expression and increased hepatic 
ATP levels, which would favour operation of apoptosis (and this 
was observed) rather than ROS-mediated necrosis (Larter and 
Farrell, unpublished data). Combined use of M30 and full-length 
CK8/18 in patients with NASH indicates that both apoptosis 
and necrosis occur in humans with the inflammatory form of 
NAFLD.
195 It is therefore possible that neutrophil accumulation 
is associated with necrosis in NASH, and it may be regulated by 
different pathways than those important for macrophage and 
lymphocyte recruitment and activation.
87 These important and 
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FUTURE DIRECTIONS, CLINICAL AND THERAPEUTIC IM-
PLICATIONS 
The two hits concept of NASH pathogenesis served to dis-
sect injury and pro-inflammatory pathways from the metabolic 
causes of steatosis. Insights gained since then indicate that the 
lipid molecules that accumulate, together with TG, in some 
NAFLD livers can themselves participate directly in pathogen-
esis of the necroinflammatory element of NASH. The fact that 
steatosis (which biochemically is TG accumulation) does not 
inevitably predispose to NASH is better understood by recent 
studies showing that TG formation is protective against injury 
and inflammation, not predisposing to such inflammation.
235,236 
On the other hand, FC, certain FFA, DAG and some phospholip-
ids can directly injury liver cells and mediate subcellular stresses 
(mitochondrial, ER, oxidative) that incite hepatocellular injury, 
cell death and inflammatory recruitment in NASH. Thus, the es-
sential difference between the two extremes of liver pathology 
(NASH versus not-NASH) is not attributable to the amount of 
fat (TG) in the liver, but rather the type of lipid molecules that 
accumulate. 
Research in NASH pathogenesis has reached the exciting 
stage where investigation of potential lipotoxic molecules is be-
ing refined. Arguably the most critical future direction, however, 
is to perform more definitive lipidomic studies in human liver 
so as to clearly identify which lipid species are unambiguously 
implicated, and the genetic and environmental reasons for their 
accumulation. Such measurements must also establish correla-
tions between candidate lipotoxic mediators, pro-inflammatory 
(and pro-fibrotic) pathways and liver pathology. In lieu of such 
human data, researchers (and journal editors) might better fo-
cus their attention on models where development of NAFLD 
across the pathological spectrum that includes NASH is clearly 
related at least to over-nutrition and insulin resistance, and ide-
ally to obesity, type 2 diabetes and hypoadiponectinemia, the 
metabolic determinants of human NASH.
2,3 Other models have 
taught us what can occur in steatohepatitis pathogenesis, but 
hepatologists are most interested in what does occur in NASH. 
Therefore, nutritional depletion models like the MCD dietary 
model developed in the author’s laboratory in 1996, choline 
deficiency, the CDDAA and similar deprivations, 2% cholesterol 
(equivalent to 20 kg of cholesterol a day for humans!) plus 
cholate diets, or genetic knockout and knock-in models of dis-
ordered adipokine (leptin, adiponectin) or lipid and cholesterol 
handling should no longer, in our view, receive the high level 
of current attention simply because of the “cute” reductionist 
science used, when clinically more relevant (and equally con-
venient) alternatives have been characterized metabolically and 
pathologically.
108,109,135
Establishing whether the pro-inflammatory pathways in 
NASH eminate from hepatocytes subjected mitochondrial in-
jury, impaired autophagy, the inflammasome, or from processes 
like ER stress, oxidative stress/necrosis, senescence and p53 
expression is pertinent to the design of novel, mechanism-based 
therapies for NASH. Current approaches, vitamin E, PPAR-γ 
(“glitazone”) agonists, ursodeoxycholic acid, lipase inhibitors, 
generally effect some reduction in steatosis severity, but effects 
on inflammation are less consistent (ezetimibe may be an ex-
ception), and there are few reliable reports of fibrosis reduction. 
Despite interest in the gut-liver axis in obesity, type 2 diabetes 
and NAFLD, there are few data on clinical improvement with 
use of probiotics, other measures to alter the intestinal micro-
biota or use of incretin mimetics. Only bariatric surgery, or 
other effective means of weight loss coupled to increased physi-
cal activity that improve insulin sensitivity seem to combat 
both steatosis and inflammation in NASH. We therefore need to 
learn whether this is because of a primary effect on improving 
insulin sensitivity and reducing hyperinsulinemia, with possible 
secondary changes to turnover and storage of hepatotoxic lipid 
species,
237 such as we recently clarified for disordered hepatic 
cholesterol homeostasis.
115 If so, the findings could direct a radi-
cally different therapeutic approach, perhaps even finding a 
cure for NASH without what seems presently to be essential- a 
change in lifestyle and a decrease in body weight. 
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